156 results
D
TNFA
TNF Pharmaceuticals Inc.
31 May 24
$15.15 mm in equity / options / securities to be acquired, sold $15.15 mm, 5 investors
8:00am
materials under this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
D
TNFA
TNF Pharmaceuticals Inc.
31 May 24
$26.85 mm in equity / options / securities to be acquired, sold $26.85 mm, 4 investors
8:00am
materials under this undertaking or otherwise and can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
8-K
EX-3.1
TNFA
TNF Pharmaceuticals Inc.
23 May 24
Material Modifications to Rights of Security Holders
4:05pm
or written consents (and copies of proxy materials and other information sent to stockholders) with respect to which they would be entitled to vote
8-K
EX-3.2
13d n7whfe4awg2
23 May 24
Material Modifications to Rights of Security Holders
4:05pm
8-K
EX-3.2
loxta678
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
8-K
EX-3.1
z05v 3sxwou
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
8-K
EX-10.2
ftz616
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
8-K
EX-10.1
sfj9vfw6ry7zt23h1
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
8-K
EX-3.1
ik2y9k84kbc32uzwyq
8 Apr 24
Entry into a Material Definitive Agreement
4:49pm
8-K
EX-3.1
x5nj ioc2k2azvfq1tt
7 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-3.2
801uqu84 wda
7 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
qgx3do2jtp3u8v
5 Mar 24
Regulation FD Disclosure
11:00am
8-K
gdozjl5bpk49g
13 Feb 24
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
4:57pm
8-K
u6xq1nfr1
6 Dec 23
Regulation FD Disclosure
9:15am
8-K
9gzm3o
19 Oct 23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
9:00am
8-K
4441ih 7b
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
8-K
tig7 ixsgg
14 Aug 23
Regulation FD Disclosure
8:30am